• Increase font size
  • Default font size
  • Decrease font size

Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums

Print E-mail
Wednesday, 08 July 2009 16:20
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration to market its over-the-counter Nicotine Polacrilex Gum USP, 2 mg and 4 mg strengths in the coated fruit and cinnamon flavors.

Nicotine Polacrilex Gum coated fruit and cinnamon flavors are the generic equivalent of GlaxoSmithKline Consumer Healthcare's Nicorette Fruit Chill(R) and Cinnamon Surge(TM) Coated gums, which are used as an aid to smoking cessation. The market for over-the-counter nicotine gum had annual sales of over $305 million for the twelve months ending March 2009, according to IRI sales data. Watson will make the products available to customers immediately.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.




BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 3 hours ago Medgenics ($MDGN) up 10% on Monday! We first told you about the firm last Friday: http://t.co/aD50CMSH
about 3 hours ago Thinly traded BioLineRx shares move on hepatitis C deal: The shares of thinly traded BioLineRx (NASDAQ:BLRX) soa... http://t.co/ugbuZgNN
about 8 hours ago Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment; Acorda Announces Launch of Generic ... http://t.co/vSt6VrLP
about 13 hours ago $CVM up 17% and technically looks like it may head higher.
about 18 hours ago $ANAC drops after GlaxoSmithKline (GSK) pauses enrollment for its clinical trials of its urinary tract infection drug. http://t.co/yUUSzkUr
about 19 hours ago Catalysts on tap for Corcept: Corcept Therapeutics (NASDAQ:CORT) is a drug discovery company focused on the deve... http://t.co/jd3C1ddH
about 20 hours ago Commented on: "Will Celsion's Upcoming Catalysts Help The Price Break-Out Stick?" http://t.co/dJ0reUFR $BSX $PHG $MDSO $CLSN
about 20 hours ago Monday morning watch -- European Leaders Maintain Pressure on Greece to Complete Terms for Bailout - http://t.co/0wipY6QB via @BloombergNews

navigation

Free Phone Trade Alerts